Drugs / PEV301
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00513669 | Jan 2008 → Mar 2009 | Plasmodium falciparum malaria | Swiss Tropical & Public Health Institute | Completed | No outcome recorded |
| Phase 1 | NCT00400101 | Nov 2003 → Oct 2005 | Plasmodium falciparum malaria | Swiss Tropical & Public Health Institute | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PEV 301 | “Virosomal formulations of the antigens (designated PEV301 and PEV302 for the AMA-1 and the CSP virosomal vaccine, respectively) or unmodified virosomes were injected i. m. on...” NCT00400101 ↗ |
| Modality | Vaccine | “two virosome formulated anti-malaria vaccine components (PEV 301 and PEV 302) administered in combination” NCT00513669 ↗ |
| Route | Intramuscular | “were injected i. m. on days 0, 60 and 180.” NCT00400101 ↗ |